BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26733502)

  • 1. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours.
    Vitali E; Cambiaghi V; Zerbi A; Carnaghi C; Colombo P; Peverelli E; Spada A; Mantovani G; Lania AG
    Endocr Relat Cancer; 2016 Mar; 23(3):181-90. PubMed ID: 26733502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
    Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
    Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
    Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
    Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells.
    Peverelli E; Giardino E; Treppiedi D; Vitali E; Cambiaghi V; Locatelli M; Lasio GB; Spada A; Lania AG; Mantovani G
    Endocrinology; 2014 Aug; 155(8):2932-41. PubMed ID: 24828612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors.
    Vitali E; Piccini S; Trivellin G; Smiroldo V; Lavezzi E; Zerbi A; Pepe G; Lania AG
    Mol Cell Endocrinol; 2021 May; 527():111226. PubMed ID: 33675866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
    Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E
    Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.
    Cambiaghi V; Vitali E; Morone D; Peverelli E; Spada A; Mantovani G; Lania AG
    Endocrine; 2017 Apr; 56(1):146-157. PubMed ID: 27406390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
    Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
    Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
    Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
    Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST
    Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation.
    Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells.
    Carrere N; Vernejoul F; Souque A; Asnacios A; Vaysse N; Pradayrol L; Susini C; Buscail L; Cordelier P
    Hum Gene Ther; 2005 Oct; 16(10):1175-93. PubMed ID: 16218779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP/PKA dependent phosphorylation.
    Peverelli E; Giardino E; Vitali E; Treppiedi D; Lania AG; Mantovani G
    Horm Metab Res; 2014 Nov; 46(12):845-53. PubMed ID: 25068602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?
    Körner M; Waser B; Reubi JC
    Neuroendocrinology; 2015; 101(1):45-57. PubMed ID: 25591947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLNA expression modulates pathological markers of pituitary neuroendocrine tumours.
    Toledo J; Perez PA; Zanetti M; Díaz-Torga G; Mukdsi JH; Gutierrez S
    J Endocrinol; 2024 Jan; 260(1):. PubMed ID: 37855268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway.
    Najib S; Saint-Laurent N; Estève JP; Schulz S; Boutet-Robinet E; Fourmy D; Lättig J; Mollereau C; Pyronnet S; Susini C; Bousquet C
    Mol Cell Biol; 2012 Mar; 32(5):1004-16. PubMed ID: 22203038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.